Serina Therapeutics, Inc.

Serina Therapeutics, Inc. (ticker: SER) is an NYSE-listed pharmaceutical preparations company. DredgeCap's structured extraction of SER's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. SER reported $130K in revenue and -$6.90M for the period ending 2025-12-31, with operating cash flow of -$4.57M. Cash and equivalents stood at $24.53M (up 474.8% year-over-year). Total assets of $27.30M exceed total liabilities of $9.67M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

SER Cash Runway

Months-of-runway analysis for SER, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on SER

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.